New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
This study is to investigate the therapeutic efficacy and side effect of chidamide,
azacitidine combined with priming HAG regimen for relapsed or refractroy acute myeloid
leukemia
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Collaborators:
Anhui Provincial Hospital First Affiliated Hospital of Harbin Medical University Fujian Medical University Union Hospital Nanfang Hospital of Southern Medical University Qilu Hospital of Shandong University Ruijin Hospital Shandong Provincial Hospital The Affiliated Cancer Hospital of Zhengzhou University The First Hospital of Jilin University West China Hospital Xinqiao Hospital of Chongqing